title: Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma.
abstract: To evaluate the effectiveness and safety of autologous cytokine-induced killer (CIK) cells in elderly patients with diffuse large B-cell lymphoma. Peripheral blood mononuclear cells (PBMC) were isolated from nine elderly patients with diffuse large B-cell lymphoma. PBMCs were augmented by priming with interferon gamma (IFN-γ) followed by IL-2 and monoclonal antibody (mAb) against CD3. Autologous CIK cells (range 5 × 10(9)-1 × 10(10)) were then infused back to individual patients; infusion was repeated every 4 weeks for 32 weeks (eight cycles). Patients were assessed for changes in lymphocyte subgroup, tumor-related biological parameters, imaging characteristics, the condition of remission, quality of life (QOL), and survival. Prior to CIK infusion, two patients were in complete remission and seven patients were in partial remission. After autologous CIK cell transfusions, the proportion of CD3+, CD3+CD8+, and CD3+CD56+ cells were significantly increased compared with baseline (P < 0.05); whereas serum levels of β2-microglobulin and LDH were significantly decreased (P < 0.05). The lymphoma symptoms were reduced and QOL was improved (P < 0.05) in all patients. All patients achieved complete remission at study endpoint. No adverse reactions were reported. Autologous CIK cell immunotherapy is safe and efficacious for the treatment of elderly patients with diffuse large B-cell lymphoma.
authors.affiliation: Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China. xuechun1111@126.com
authors.forename: Xue-chun
authors.initials: XC
authors.lastname: Lu
authors.forename: Bo
authors.initials: B
authors.lastname: Yang
authors.forename: Rui-li
authors.initials: RL
authors.lastname: Yu
authors.forename: Xiao-hua
authors.initials: XH
authors.lastname: Chi
authors.forename: Shuai
authors.initials: S
authors.lastname: Tuo
authors.forename: Chao-wei
authors.initials: CW
authors.lastname: Tuo
authors.forename: Hong-li
authors.initials: HL
authors.lastname: Zhu
authors.forename: Yao
authors.initials: Y
authors.lastname: Wang
authors.forename: Chao-guang
authors.initials: CG
authors.lastname: Jiang
authors.forename: Xiao-bing
authors.initials: XB
authors.lastname: Fu
authors.forename: Yang
authors.initials: Y
authors.lastname: Yang
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.forename: Shan-qian
authors.initials: SQ
authors.lastname: Yao
authors.forename: Han-ren
authors.initials: HR
authors.lastname: Dai
authors.forename: Lili
authors.initials: L
authors.lastname: Cai
authors.forename: Bing-jun
authors.initials: BJ
authors.lastname: Li
authors.forename: Wei-dong
authors.initials: WD
authors.lastname: Han
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D017252:CD3 Complex / Q000276:immunology / Q000378:metabolism; D019002:CD56 Antigen / Q000378:metabolism; D016827:CD8 Antigens / Q000378:metabolism; D002478:Cells, Cultured; D055612:Cytokine-Induced Killer Cells / Q000276:immunology / Q000637:transplantation*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007371:Interferon-gamma / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D008259:Macroglobulins / Q000032:analysis; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D019002:CD56 Antigen; D016827:CD8 Antigens; D007376:Interleukin-2; D008259:Macroglobulins; D007371:Interferon-gamma; D007770:L-Lactate Dehydrogenase